Equities analysts expect that Inovalon Holdings, Inc. (NASDAQ:INOV) will report sales of $194.47 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Inovalon’s earnings, with the lowest sales estimate coming in at $192.70 million and the highest estimate coming in at $195.40 million. Inovalon reported sales of $161.38 million during the same quarter last year, which would suggest a positive year over year growth rate of 20.5%. The firm is scheduled to announce its next earnings results on Wednesday, October 27th.
On average, analysts expect that Inovalon will report full-year sales of $770.75 million for the current fiscal year, with estimates ranging from $767.81 million to $775.90 million. For the next fiscal year, analysts anticipate that the business will post sales of $862.13 million, with estimates ranging from $829.23 million to $885.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Inovalon.
Inovalon (NASDAQ:INOV) last issued its quarterly earnings data on Wednesday, July 28th. The technology company reported $0.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.02. The business had revenue of $190.44 million during the quarter, compared to the consensus estimate of $183.89 million. Inovalon had a net margin of 5.55% and a return on equity of 11.72%.
Shares of NASDAQ:INOV traded down $0.02 during mid-day trading on Friday, reaching $40.39. The company had a trading volume of 2,223,429 shares, compared to its average volume of 685,153. Inovalon has a one year low of $17.56 and a one year high of $40.99. The company has a current ratio of 2.23, a quick ratio of 2.23 and a debt-to-equity ratio of 1.21. The company’s 50-day moving average price is $37.88 and its 200-day moving average price is $32.86. The firm has a market cap of $6.31 billion, a price-to-earnings ratio of 149.60, a PEG ratio of 2.60 and a beta of 0.59.
A number of large investors have recently modified their holdings of INOV. Eaton Vance Management lifted its stake in Inovalon by 243.8% during the first quarter. Eaton Vance Management now owns 2,350,167 shares of the technology company’s stock worth $67,638,000 after purchasing an additional 1,666,534 shares during the last quarter. Oak Ridge Investments LLC purchased a new position in shares of Inovalon during the first quarter worth approximately $46,906,000. ArrowMark Colorado Holdings LLC lifted its holdings in shares of Inovalon by 77.8% in the 2nd quarter. ArrowMark Colorado Holdings LLC now owns 3,255,534 shares of the technology company’s stock worth $110,949,000 after acquiring an additional 1,424,789 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Inovalon by 241.3% in the 1st quarter. Royal Bank of Canada now owns 992,763 shares of the technology company’s stock valued at $28,572,000 after purchasing an additional 701,883 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Inovalon by 241.8% during the 2nd quarter. Millennium Management LLC now owns 735,237 shares of the technology company’s stock valued at $25,057,000 after purchasing an additional 520,104 shares during the last quarter. 35.82% of the stock is owned by institutional investors.
Inovalon Company Profile
Inovalon Holdings, Inc engages in the development of cloud-based platforms for the healthcare industry. Its products include datasets, integration technologies, predictive analytics, and related services. The company was founded in 1998 and is headquartered in Bowie, MD.
See Also: Death Cross
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.